Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer
Cancer Science · 2024
DOI: 10.1111/cas.16234 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Science, 2024. Verfasst von Hiroji Iwata und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Ado-Trastuzumab Emtansine, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Trastuzumab. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daiichi Sankyo, Daiichi Sankyo Europe.
Abstract (Originalsprache)
The global phase 3 DESTINY‐Breast03 study ( ClinicalTrials.gov ; NCT03529110) showed statistically significant and clinically meaningful improvements in progression‐free survival (PFS) and overall survival (OS) with trastuzumab deruxtecan (T‐DXd) over trastuzumab emtansine (T‐DM1) in patients with human epidermal growth factor receptor 2 (HER2)‐positive metastatic breast cancer (mBC) previously treated with trastuzumab and a taxane. Here, we report a subgroup analysis of Asian patients enrolled in DESTINY‐Breast03. In total, 309 patients (149 in the T‐DXd arm and 160 in the T‐DM1 arm) from Asian countries and regions were randomized. At data cutoff (July 25, 2022), the median duration of follow‐up in the Asian subpopulation was 29.0 months with T‐DXd and 26.0 months with T‐DM1. The PFS (determined by blinded independent central review) hazard ratio was 0.30 (95% confidence interval 0.22–0.41) favoring T‐DXd over T‐DM1 (median PFS 25.1 vs. 5.4 months). Median OS was not reached in the T‐DXd arm and was 37.7 months in the T‐DM1 arm. The median treatment duration was 15.4 months with T‐DXd and 5.5 months with T‐DM1. The incidence of grade ≥3 drug‐related treatment‐emergent adverse events was similar between both treatment arms (49.0% vs. 46.5%) and was consistent with the overall DESTINY‐Breast03 population. Adjudicated drug‐related interstitial lung disease or pneumonitis occurred in 12.9% of patients treated with T‐DXd and 2.5% treated with T‐DM1, with a higher incidence in Japanese patients; none of these were grade ≥4 events. These efficacy and safety data reinforce the favorable benefit–risk profile of T‐DXd in HER2‐positive mBC, including in the Asian subgroup.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
- Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Samsung Medical Center, Seoul, Korea.
- Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
ORCID-Profile: Hiroji Iwata
Förderung
- Daiichi Sankyo
- Daiichi Sankyo Europe
Zitieren
APA
Iwata, H., Xu, B., Kim, S. B., Chung, W. P., Park, Y. H., Kim, M. H., Tseng, L. M., Chung, C. F., Huang, C. S., Kim, J. H., Chiu, J. W. Y., Yamashita, T., Li, W., Egorov, A., Nishijima, S., Nakatani, S., Nishiyama, Y., Sugihara, M., Cortés, J., & Im, S. A. (2024). Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer. Cancer Science. https://doi.org/10.1111/cas.16234
Vancouver
Iwata H, Xu B, Kim SB, Chung WP, Park YH, Kim MH, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer. Cancer Science. 2024. doi:10.1111/cas.16234
BibTeX
@article{Iwata2024,
author = {Iwata, Hiroji and Xu, Binghe and Kim, Sung-Bae and Chung, Wei-Pang and Park, Yeon Hee and Kim, Min Hwan and Tseng, Ling-Ming and Chung, Chi-Feng and Huang, Chiun-Sheng and Kim, Jee Hyun and Chiu, Joanne Wing Yan and Yamashita, Toshinari and Li, Wei and Egorov, Anton and Nishijima, Soichiro and Nakatani, Shunsuke and Nishiyama, Yuji and Sugihara, Masahiro and Cortés, Javier and Im, Seock-Ah},
title = {Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16234}
}
EUVIMED